Home › Companies › Catalyst Pharmaceuticals, Inc. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Catalyst Pharmaceuticals, Inc.’s Form 8-K, filed May 23, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 20, 2025: 9 items on Catalyst Pharmaceuticals, Inc.’s Form 8-K, filed May 23, 2025: 9 passed (calculated).
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025
Explore Catalyst Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Catalyst Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 23, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Richard J. Daly | 87,947,782 | 1,372,592 | 102,057 | -- | 11,793,160 | 98% | Passed (calculated) | — |
| Elect Director: Patrick J. McEnany | 82,282,446 | 7,039,324 | 100,661 | -- | 11,793,160 | 92% | Passed (calculated) | — |
| Elect Director: Donald A. Denkhaus | 87,993,958 | 1,329,212 | 99,261 | -- | 11,793,160 | 99% | Passed (calculated) | — |
| Elect Director: Molly Harper | 88,259,042 | 1,040,685 | 122,704 | -- | 11,793,160 | 99% | Passed (calculated) | — |
| Elect Director: Tamar Thompson | 85,761,231 | 3,562,397 | 98,803 | -- | 11,793,160 | 96% | Passed (calculated) | — |
| Elect Director: David S. Tierney | 84,527,122 | 4,751,403 | 143,906 | -- | 11,793,160 | 95% | Passed (calculated) | — |
| 2. Approval of an amendment to our 2018 Stock Incentive Plan | 85,350,862 | 3,975,602 | 95,967 | -- | 11,793,160 | 96% | Passed (calculated) | — |
| 3. Approval, on an advisory basis, of the 2024 compensation of our named executive officers | 82,734,939 | 6,484,020 | 203,472 | -- | 11,793,160 | 93% | Passed (calculated) | — |
| 4. Ratification of the selection of Grant Thornton, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 | 99,942,142 | 1,211,668 | 61,781 | -- | -- | 99% | Passed (calculated) | — |
Source: Catalyst Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 23, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
390 asset managers disclosed a vote on at least one Catalyst Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Catalyst Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect David S. Tierney, M.D. as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until his earlier death, disability or resignation:
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David S. Tierney”): 84,527,122 for, 4,751,403 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 115 asset managers below reported 42,696,336 for, 514,923 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,240,979 | 4,684 | 0 | 0 | For |
| State Street | 2,953,628 | 148 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 329,643 | 0 | 0 | Against |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 115 asset managers. All 115 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect Donald A. Denkhaus as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until his earlier death, disability or resignation:
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Donald A. Denkhaus”): 87,993,958 for, 1,329,212 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 115 asset managers below reported 43,065,158 for, 146,100 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,240,985 | 4,677 | 0 | 0 | For |
| State Street | 2,953,776 | 0 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 115 asset managers. All 115 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect Molly Harper as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until her earlier death, disability or resignation:
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Molly Harper”): 88,259,042 for, 1,040,685 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 115 asset managers below reported 43,194,560 for, 16,699 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,240,986 | 4,677 | 0 | 0 | For |
| State Street | 2,953,776 | 0 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 115 asset managers. All 115 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect Patrick J. McEnany as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until his earlier death, disability or resignation:
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Patrick J. McEnany”): 82,282,446 for, 7,039,324 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 115 asset managers below reported 40,203,681 for, 3,007,578 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,240,984 | 4,678 | 0 | 0 | For |
| State Street | 63,822 | 2,889,954 | 0 | 0 | Against |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 115 asset managers. All 115 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect Richard J. Daly as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until his earlier death, disability or resignation:
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Richard J. Daly”): 87,947,782 for, 1,372,592 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 115 asset managers below reported 43,200,911 for, 10,348 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,245,660 | 3 | 0 | 0 | For |
| State Street | 2,953,628 | 148 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 115 asset managers. All 115 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect Tamar Thompson as a member of the Board of Directors until the 2026 Annual Meeting of Stockholders, or until her earlier death, disability or resignation:
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Tamar Thompson”): 85,761,231 for, 3,562,397 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 115 asset managers below reported 42,516,184 for, 695,075 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,231,829 | 582,131 | 0 | 0 | For |
| Vanguard | 8,240,980 | 4,683 | 0 | 0 | For |
| State Street | 2,953,776 | 0 | 0 | 0 | For |
| Fidelity | 2,815,752 | 96,214 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 115 asset managers. All 115 are in the interactive database (link above).
1% of fund votes cast · no official result
The 111 asset managers below reported 522,658 for, 42,481,526 against, 57,208 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 0 | 12,813,960 | 0 | 0 | Against |
| Vanguard | 11,898 | 8,233,764 | 1 | 0 | Against |
| State Street | 5,108 | 2,948,668 | 0 | 0 | Against |
| Fidelity | 0 | 2,911,966 | 0 | 0 | Against |
| Dimensional | 0 | 1,600,257 | 0 | 0 | Against |
| TIAA | 0 | 1,236,505 | 0 | 0 | Against |
| Charles Schwab | 0 | 1,202,971 | 0 | 0 | Against |
| Royce | 0 | 1,141,617 | 0 | 0 | Against |
| Pacer Funds Trust | 0 | 854,367 | 0 | 0 | Against |
| Invesco | 0 | 829,473 | 0 | 0 | Against |
| T. Rowe Price | 0 | 719,930 | 0 | 0 | Against |
| Waddell & Reed | 0 | 634,570 | 0 | 0 | Against |
| American Century | 0 | 491,036 | 0 | 0 | Against |
| OBERWEIS FUNDS | 0 | 467,100 | 0 | 0 | Against |
| Goldman Sachs | 0 | 391,456 | 0 | 0 | Against |
| Aberdeen | 0 | 329,643 | 0 | 0 | Against |
| Equitable | 0 | 294,963 | 0 | 0 | Against |
| World Funds Trust | 0 | 266,124 | 0 | 0 | Against |
| Northern Trust | 0 | 263,318 | 0 | 0 | Against |
| Janus Detroit Street Trust | 0 | 257,889 | 0 | 0 | Against |
| SEI | 0 | 256,097 | 0 | 0 | Against |
| Prudential/PGIM | 0 | 243,921 | 0 | 0 | Against |
| First Trust | 0 | 236,665 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 236,483 | 0 | 0 | Against |
| Jackson National | 0 | 224,018 | 0 | 0 | Against |
Showing the 25 largest of 111 asset managers. All 111 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To approve an amendment to our 2018 Stock Incentive Plan to increase the shares available for issuance by 5 million shares.
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“2. Approval of an amendment to our 2018 Stock Incentive Plan”): 85,350,862 for, 3,975,602 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 122 asset managers below reported 42,590,578 for, 687,524 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,245,656 | 7 | 0 | 0 | For |
| State Street | 2,953,628 | 148 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 0 | 491,036 | 0 | 0 | Against |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. All 122 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To approve, on an advisory basis, the 2024 compensation of our named executive officers.
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“3. Approval, on an advisory basis, of the 2024 compensation of our named executive officers”): 82,734,939 for, 6,484,020 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Catalyst Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Say on pay” (2 managers, 498 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,240,978 | 4,685 | 0 | 0 | For |
| State Street | 2,952,581 | 1,195 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 0 | 829,473 | 0 | 0 | Against |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 0 | 491,036 | 0 | 0 | Against |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 329,643 | 0 | 0 | Against |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 245,744 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
Fund voting reports, all 113 managers: 41,406,192 for, 1,787,109 against, 108,148 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 5,128,898 | 37,458 | 0 | 0 | For |
| BlackRock | 4,710,517 | 27,382 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,755,989 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2,598,901 | 0 | 0 | 0 | For |
| Fundsmith LLP | 0 | 2,151,274 | 0 | 0 | Against |
| Renaissance | 1,418,682 | 0 | 0 | 0 | For |
| Charles Schwab | 1,324,513 | 0 | 0 | 0 | For |
| Nuveen | 1,248,350 | 0 | 0 | 0 | For |
| Boston Partners | 1,176,609 | 0 | 0 | 0 | For |
| Northern Trust | 1,148,050 | 5,449 | 0 | 0 | For |
| Invesco | 0 | 1,066,045 | 0 | 0 | Against |
| T. Rowe Price | 1,044,048 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 950,798 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 942,298 | 0 | 0 | 0 | For |
| Goldman Sachs | 765,572 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 734,054 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 721,880 | 0 | 0 | Against |
| JUPITER ASSET MANAGEMENT LTD | 661,020 | 0 | 0 | 0 | For |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 540,691 | 89,787 | 0 | 0 | Mixed |
| PRINCIPAL GLOBAL INVESTORS | 617,506 | 0 | 0 | 0 | For |
| MetLife Investment Management, LLC | 130,559 | 474,582 | 0 | 0 | Mixed |
| American Century | 0 | 526,569 | 0 | 0 | Against |
| OBERWEIS ASSET MANAGEMENT INC/ | 467,100 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 426,807 | 0 | 0 | 0 | For |
| Allianz | 0 | 423,958 | 0 | 0 | Against |
Institutional-manager reports, all 299 managers: 39,907,857 for, 7,181,227 against, 400 abstained, 4,342 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To ratify the selection of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
Catalyst Pharmaceuticals, Inc.’s own tally for this item (“4. Ratification of the selection of Grant Thornton, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 99,942,142 for, 1,211,668 against, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Catalyst Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 115 asset managers below reported 43,084,022 for, 127,237 against, 24,148 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 12,813,960 | 0 | 0 | 0 | For |
| Vanguard | 8,245,661 | 2 | 0 | 0 | For |
| State Street | 2,953,628 | 148 | 0 | 0 | For |
| Fidelity | 2,911,966 | 0 | 0 | 0 | For |
| Dimensional | 1,600,257 | 0 | 0 | 0 | For |
| TIAA | 1,236,505 | 0 | 0 | 0 | For |
| Charles Schwab | 1,202,971 | 0 | 0 | 0 | For |
| Royce | 1,141,617 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 854,367 | 0 | 0 | 0 | For |
| Invesco | 829,473 | 0 | 0 | 0 | For |
| T. Rowe Price | 719,930 | 0 | 0 | 0 | For |
| Waddell & Reed | 634,570 | 0 | 0 | 0 | For |
| American Century | 491,036 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 467,100 | 0 | 0 | 0 | For |
| Goldman Sachs | 391,456 | 0 | 0 | 0 | For |
| Aberdeen | 329,643 | 0 | 0 | 0 | For |
| Equitable | 294,963 | 0 | 0 | 0 | For |
| World Funds Trust | 266,124 | 0 | 0 | 0 | For |
| Northern Trust | 263,318 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 257,889 | 0 | 0 | 0 | For |
| SEI | 256,097 | 0 | 0 | 0 | For |
| Prudential/PGIM | 243,921 | 0 | 0 | 0 | For |
| First Trust | 236,665 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 236,483 | 0 | 0 | 0 | For |
| Jackson National | 224,018 | 0 | 0 | 0 | For |
Showing the 25 largest of 115 asset managers. All 115 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 121,959,172 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 10.51% |
| 2 | Vanguard | 6.76% |
| 3 | State Street | 2.42% |
| 4 | Fidelity | 2.39% |
| 5 | Dimensional | 1.31% |
| 6 | TIAA | 1.01% |
| 7 | Charles Schwab | 0.99% |
| 8 | Royce | 0.94% |
| 9 | Pacer Funds Trust | 0.70% |
| 10 | Invesco | 0.68% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | State Street | 4.24% |
| 2 | BlackRock | 3.88% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 2.26% |
| 4 | DEERFIELD MANAGEMENT COMPANY, L.P. | 2.13% |
| 5 | Fundsmith LLP | 1.76% |
| 6 | Renaissance | 1.16% |
| 7 | Charles Schwab | 1.09% |
| 8 | Nuveen | 1.02% |
| 9 | Boston Partners | 0.96% |
| 10 | Northern Trust | 0.95% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 18,804,335 | 15.42% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 8,495,580 | 6.97% | Form 13F, quarter ended March 31, 2025 |
| State Street | 5,530,437 | 4.53% | Form 13F, quarter ended March 31, 2025 |
| Goldman Sachs | 3,135,473 | 2.57% | Form 13F, quarter ended March 31, 2025 |
| Deerfield Mgmt, L.P. | 3,133,011 | 2.57% | Schedule 13G, filed February 13, 2025 |
| Renaissance Technologies | 2,956,316 | 2.42% | Form 13F, quarter ended March 31, 2025 |
| Geode Capital | 2,765,556 | 2.27% | Form 13F, quarter ended March 31, 2025 |
| Morgan Stanley | 2,394,555 | 1.96% | Form 13F, quarter ended March 31, 2025 |
| Dimensional Fund Advisors | 2,187,422 | 1.79% | Form 13F, quarter ended March 31, 2025 |
| Northern Trust | 1,486,198 | 1.22% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 121,959,172 shares outstanding, as reported by Catalyst Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Catalyst Pharmaceuticals, Inc.'s shareholder meeting held May 20, 2025, in the 2024-2025 proxy season, 390 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 4,149 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the 2024 compensation of our named executive officers. — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Catalyst Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 23, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Catalyst Pharmaceuticals, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Catalyst Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page).
Proxy Votes Now, “Catalyst Pharmaceuticals, Inc. 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/catalyst-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.